Abstract: Objective To investigate the level of 25-hydroxyvitamin D in the peripheral blood of patients with hepatocellular carcinoma and to evaluate its clinical significance. Methods The 65 patients with hepatocellular carcinoma admitted in our hospital and 80 healthy volunteers were recruited, and the levels of 25-hydroxyvitamin D in their peripheral blood samples were detected by enzymelinked immunosorbent assay (ELISA) method, and the results were statistically analyzed. Besides, the differences of the 25-hydroxyvitamin D levels of the hepatocellular carcinoma patients with different TNM stages were also analyzed simutaneously. Results The 25-hydroxyvitamin D level of the peripheral blood in patients with hepatocellular carcinoma was (28.132 ± 10.82 ) nmol/L, which was significantly lower than that of healthy volunteers [(45.635 ± 9.23 nmol/L, P = 0.000)]; and there were no significant difference among the different TNM staging in patients with hepatocellular carcinoma in peripheral blood of the 25-hydroxyvitamin D, the P value was 0.122. Conclusions The present study
showed that the 25-hydroxyvitamin D level of the peripheral blood in patients with hepatocellular carcinoma is significantly lower than that of healthy volunteers, which implies that the reduction of the 25-hydroxyvitamin D level in the peripheral blood may closely associated with the occurrence and the development of hepatocellular carcinoma, and this result may be helpful to understand the pathogenesis and find new therapy for hepatocellular carcinoma.